Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,132.37
(
-0.70%
)
News Focus
News Focus

Replies to post #187903 on Biotech Values

Replies to #187903 on Biotech Values
icon url

DewDiligence

02/26/15 9:19 AM

#187905 RE: pastemp #187903

About $200M peak annual sales in the US, IMO.
icon url

DewDiligence

03/02/15 5:29 PM

#188035 RE: pastemp #187903

OCRX—Do you have a sense what the potential market size could be for this drug?

I previously replied to your question by saying $200M peak annual sales in the US (#msg-111197726). This number is for the IV formulation only, which is the formulation being tested in all of the existing clinical trials.

OCRX’s own peak-sales projection is much higher: $1.5B, consisting of $500-600M from the (existing) IV formulation and $800-900M from the (TBD) oral formulation. Please see slide #25 at http://www.sec.gov/Archives/edgar/data/1274644/000110465915015513/a15-5631_1ex99d1.htm .